Decline in COVID-19 sales hits GSK revenue

26 April 2023
gsk_big

GSK (LSE: GSK) reported a 3% drop in its first-quarter sales compared to a year ago.

The UK drugmaker’s quarterly revenue came in at £6.95 billion ($8.7 billion), which was nonetheless above the £6.5 billion anticipated by analysts.

"We are very focused on our upcoming launches, including our potential RSV older adult vaccine"Excluding COVID-19 related sales, which came to £1.3 billion in the first quarter of 2022, the group's turnover grew by 10%, which shows how the easing off of the pandemic has impacted GSK’s sales.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical